Role of MIF -173G/C and Mbl2 codon 54A/B variants in risk of multiple myeloma: An association study.

Pehlivan M., Nursal A., Gündeş İ., Oyacı Y., Kıvanç D., Pehlivan S.

Endocrine, metabolic & immune disorders drug targets, cilt.21, ss.925-931, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21
  • Basım Tarihi: 2021
  • Doi Numarası: 10.2174/1871530320999200818102731
  • Dergi Adı: Endocrine, metabolic & immune disorders drug targets
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Biotechnology Research Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.925-931
  • Anahtar Kelimeler: Multiple myeloma, malignant disease, macrophage inhibitory factor, mannose binding lectin, variant, Turkish population, MIGRATION INHIBITORY FACTOR, MANNOSE-BINDING LECTIN, FACTOR GENE, PROMOTER POLYMORPHISMS, CANCER, LEUKEMIA, MIF, DIAGNOSIS, PATTERN, IMPACT
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background: Multiple myeloma (MM) is a malignant disease manifested by the clonal proliferation of atypical plasma cells. Macrophage inhibitory factor (MIF) is one of the pleiotropic regulators in various biological and cellular processes. Mannose-binding lectin (MBL) is a crucial protein involved in the lectin pathway of the immune system.